113 completed, 26 terminated, 5 withdrawn, 4 unknown. 64 Phase 2, 47 Phase 3, 25 Phase 1, 13 Phase 4, 6 Not applicable.
By phase and status
| Phase | Trials | Status |
|---|
| Phase 2 | 64 | Completed 43, Terminated 16, Withdrawn 3, Unknown 2 |
| Phase 3 | 47 | Completed 42, Terminated 4, Withdrawn 1 |
| Phase 1 | 25 | Completed 17, Terminated 7, Unknown 1 |
| Phase 4 | 13 | Completed 11, Terminated 1, Unknown 1 |
| Not applicable | 6 | Completed 3, Terminated 1, Unknown 1, Withdrawn 1 |
| Early Phase 1 | 1 | Completed 1 |
Follow Cephalon: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis Bendamustine, Dexamethasone - AL Amyloidosis | Phase 2 | Completed | 40 | 2013-01-01 | 2020-03-30 |
Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy Bendamustine, Ofatumumab - Diffuse Large B-Cell Lymphoma | Phase 2 | Completed | 22 | 2012-10-01 | 2017-11-22 |
Efficacy and Safety of Obatoclax Mesylate in Combination With Carboplatin and Etoposide Compared With Carboplatin and Etoposide Alone in Chemotherapy-Naive Patients With Extensive-Stage Small Cell Lung Cancer Obatoclax Mesylate, Carboplatine and Etoposide, Carboplatin and Etoposide - Extensive-stage Small Cell Lung Cancer | Phase 3 | Withdrawn | | 2012-08-01 | 2012-08-15 |
A Study to Assess the Abuse Potential of Hydrocodone Extended-Release Tablet in Recreational Opioid Users 45-mg hydrocodone bitartrate extended-release tablet (crushed or intact), Placebo - Drug Abuse | Phase 1 | Completed | 100 | 2012-03-01 | 2012-11-21 |
Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma Bendamustine, Bortezomib - Multiple Myeloma | Phase 2 | Terminated | 24 | 2011-09-01 | 2018-02-07 |
Study of Arsenic Trioxide in Small Cell Lung Cancer Arsenic Trioxide - Lung Cancer, Cancer of Lung | Phase 2 | Completed | 20 | 2011-08-01 | 2021-02-17 |
Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) Omacetaxine, Cytarabine - Leukemia | Phase 2 | Completed | 36 | 2011-07-01 | 2018-05-30 |
Effentora® in Clinical Practice - a Non-interventional Study to Evaluate Satisfaction and Tolerability Effentora® - Cancer, Pain | | Completed | 600 | 2011-07-01 | 2012-10-24 |
A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer Trastuzumab, Docetaxel, Trastuzumab, Docetaxel, Bevacizumab, Trastuzumab+Docetaxel+NPLD - Breast Cancer | Phase 2 | Completed | 100 | 2011-06-01 | 2014-05-13 |
Study of CEP-9722 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell Lymphoma CEP-9722, Gemcitabine, Cisplatin - Solid Tumors or Mantle Cell Lymphoma | Phase 1 | Completed | 24 | 2011-05-01 | 2013-01-18 |
Nuvigil in Treatment of Cancer-Related Fatigue in Chronic Myeloid Leukemia Patients Placebo, Armodafinil - Chronic Myeloid Leukemia | Not applicable | Terminated | 1 | 2011-05-01 | 2015-12-08 |
A Study to Evaluate the Pharmacokinetics of the Hydrocodone Extended-Release Tablet (CEP-33237) in Subjects With Normal Hepatic Function and Subjects With Moderate Hepatic Impairment Hydrocodone bitartrate extended-release tablet - Hepatic Impairment | Phase 1 | Completed | 16 | 2011-04-01 | 2012-04-24 |
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder Armodafinil, Placebo - Depression | Phase 3 | Completed | 399 | 2011-03-01 | 2016-05-26 |
Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma Bendamustine, Rituximab - Diffuse Large B-Cell Lymphoma, Lymphoma, Diffuse Large-Cell | Phase 2 | Completed | 23 | 2011-03-01 | 2017-05-24 |
A Study to Assess the Pharmacokinetics of the Hydrocodone Extended-Release Tablet (CEP-33237) in Subjects With Normal Renal Function and Subjects With Varying Degrees of Renal Impairment Hydrocodone Bitartrate extended-release tablet - Renal Impairment | Phase 1 | Completed | 55 | 2011-03-01 | 2012-04-24 |
Attention Modulation for Treatment of Parkinson's Disease and Dementia With Lewy Bodies Armodafinil - Parkinsons Disease, Lewy Bodies Disease | Not applicable | Withdrawn | | 2011-01-01 | 2021-08-23 |
Study to Evaluate the Safety and Efficacy of Placulumab (CEP-37247) Administered by the Transforaminal Epidural Route for the Treatment of Patients With Lumbosacral Radicular Pain Associated With Disk Herniation CEP-37247, Placebo - Sciatica | Phase 1 / Phase 2 | Completed | 98 | 2011-01-01 | 2016-07-21 |
Nuvigil or Placebo in Newly Diagnosed Malignant Glioma Nuvigil®, Placebo - Malignant Glioma | Phase 2 | Terminated | 6 | 2010-12-01 | 2013-12-16 |
Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma Bendamustine, Rituximab, Y-90 ibritumomab - Lymphoma, Follicular | Phase 2 | Completed | 39 | 2010-10-01 | 2021-05-18 |
Single Ascending-Dose Study to Characterize the Safety, Pharmacokinetics, and Pharmacodynamics of CEP-37251 in Healthy Postmenopausal Women CEP-37251, Placebo - Bone Loss, Osteoporosis | Phase 1 | Terminated | 2 | 2010-07-01 | 2014-05-12 |
Showing 20 of 148. Sign in to see all of them.
Conditions studied
Disorders of Excessive Somnolence (15) · Neoplasms (13) · Lymphoma, Non-Hodgkin (12) · Fatigue (10) · Lymphoma (9) · Leukemia (8) · Multiple Myeloma (8) · Pain (8) · Sleep Apnea, Obstructive (8) · Leukemia, Lymphocytic, Chronic, B-Cell (7) · Narcolepsy (7) · Breakthrough Pain (6) · Depression (6) · Schizophrenia (6) · Breast Neoplasms (5)
Interventions
Modafinil (46) · Bendamustine Hydrochloride (31) · Rituximab (13) · Arsenic Trioxide (12) · Bortezomib (7) · lestaurtinib (7) · Tiagabine (6) · Fentanyl (5) · ofatumumab (5) · Ascorbic Acid (4) · Docetaxel (4) · Cytarabine (3) · Dexamethasone (3) · Doxorubicin (3) · Homoharringtonine (3)
Countries
United States (124) · Canada (24) · Germany (10) · France (9) · Poland (9) · Australia (8) · Italy (7) · Hungary (6) · Puerto Rico (6) · Spain (6) · United Kingdom (6) · Bulgaria (5) · Ukraine (4) · Argentina (3) · India (3)
Top investigators
Gwendolyn Neibler, DO (2) · Jorge Cortes, MD (2) · Laurence J. van Warmerdam, MD, PhD (2) · Mark Kirschbaum, MD (2) · Philip T Ninan, MD (2) · Amitabha Mazumder, MD (1) · Andreas Hochhaus, MD Prof Dr (1) · Apostolia M. Tsimberidou, MD, PhD (1) · Bradley F Boeve, MD (1) · Bruce Cheson, MD (1) · Bruce D Cheson, MD (1) · Carlos de Castro, MD (1) · Carmen Escalante, MD (1)
Results publications
PMID 10080589, PMID 10561296, PMID 10628376, PMID 10766175, PMID 11230490, PMID 11745247, PMID 12138395, PMID 12907602, PMID 1304367, PMID 15383473, PMID 15934498, PMID 16539726, PMID 17679724, PMID 17881719, PMID 18413464, PMID 18572266, PMID 19029516, PMID 19074216, PMID 19689921, PMID 19880686, PMID 20008298, PMID 20051221, PMID 20175410, PMID 20185313, PMID 20530317, PMID 20603435, PMID 20673554, PMID 20816042, PMID 21239695, PMID 21270442, PMID 21641776, PMID 21815182, PMID 21957829, PMID 22104981, PMID 22178084, PMID 22451423, PMID 22687392, PMID 22837377, PMID 22896000, PMID 23248254, PMID 23251870, PMID 23468307, PMID 23855816, PMID 23955074, PMID 24532997, PMID 2470152, PMID 24903629, PMID 2491964, PMID 24925211, PMID 24997137
NIH funding
2009 (4), 2008 (1), F32MH075583 (1), K23CA164015 (1), P30CA008748 (1), P50AG016574 (1), R01AG015866 (1), R01HL076101 (1), R01NS042759 (1)